INTRODUCTION: Antigen-specific active immunotherapy is an investigational therapeutic approach of potential interest for bladder cancer regardless of disease stage. Clinical development of antigen-specific immunotherapeutics against bladder cancer must be preceded by assessment of the expression of relevant genes in bladder tumors. The objectives of this study (NCT01706185) were to assess the rate of expression of the MAGE-A3 and PRAME genes in bladder tumors and to investigate the feasibility of using formalin-fixed paraffin-embedded (FFPE) tumor tissues for testing. MATERIALS AND METHODS: Archived FFPE bladder tumor specimens (any stage) were tested for mRNA expression of MAGE-A3 and PRAME using antigen-specific quantitative reverse transcription polymerase chain reaction assays. Data on patients and tumor characteristics were obtained from hospital records to investigate these characteristics' possible association with the antigen expression. RESULTS: Over 92% of the 156 tumors examined gave valid antigen test results. Of the tumors with a valid test, 46.5% were MAGE-A3-positive, 32.2% were PRAME-positive and 59.7% positive for at least one of them. Exploratory analyses of possible associations between antigen expression and patient or tumor characteristics did not identify clear associations between antigen expression and any of the variables investigated. CONCLUSIONS: Assessment of tumor antigen mRNA expression by using FFPE bladder tissues was feasible. The rates of MAGE-A3-positive and PRAME-positive tumors indicate that both antigens may be interesting targets for immunotherapeutics against bladder cancer.
INTRODUCTION: Antigen-specific active immunotherapy is an investigational therapeutic approach of potential interest for bladder cancer regardless of disease stage. Clinical development of antigen-specific immunotherapeutics against bladder cancer must be preceded by assessment of the expression of relevant genes in bladder tumors. The objectives of this study (NCT01706185) were to assess the rate of expression of the MAGE-A3 and PRAME genes in bladder tumors and to investigate the feasibility of using formalin-fixed paraffin-embedded (FFPE) tumor tissues for testing. MATERIALS AND METHODS: Archived FFPE bladder tumor specimens (any stage) were tested for mRNA expression of MAGE-A3 and PRAME using antigen-specific quantitative reverse transcription polymerase chain reaction assays. Data on patients and tumor characteristics were obtained from hospital records to investigate these characteristics' possible association with the antigen expression. RESULTS: Over 92% of the 156 tumors examined gave valid antigen test results. Of the tumors with a valid test, 46.5% were MAGE-A3-positive, 32.2% were PRAME-positive and 59.7% positive for at least one of them. Exploratory analyses of possible associations between antigen expression and patient or tumor characteristics did not identify clear associations between antigen expression and any of the variables investigated. CONCLUSIONS: Assessment of tumor antigen mRNA expression by using FFPE bladder tissues was feasible. The rates of MAGE-A3-positive and PRAME-positive tumors indicate that both antigens may be interesting targets for immunotherapeutics against bladder cancer.
Authors: Jeffrey S Weber; Nicholas J Vogelzang; Marc S Ernstoff; Oscar B Goodman; Lee D Cranmer; John L Marshall; Sabrina Miles; Dar Rosario; David C Diamond; Zhiyong Qiu; Mihail Obrocea; Adrian Bot Journal: J Immunother Date: 2011-09 Impact factor: 4.456
Authors: Adalberto Costessi; Nawel Mahrour; Esther Tijchon; Rieka Stunnenberg; Marieke A Stoel; Pascal W Jansen; Dotan Sela; Skylar Martin-Brown; Michael P Washburn; Laurence Florens; Joan W Conaway; Ronald C Conaway; Hendrik G Stunnenberg Journal: EMBO J Date: 2011-08-05 Impact factor: 11.598
Authors: Padmanee Sharma; Yu Shen; Sijin Wen; Dean F Bajorin; Victor E Reuter; Lloyd J Old; Achim A Jungbluth Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: Hilary A Vaughan; Suzanne Svobodova; Duncan Macgregor; Sue Sturrock; Achim A Jungbluth; Judy Browning; Ian D Davis; Philip Parente; Yao-Tseng Chen; Elisabeth Stockert; Fiona St Clair; Lloyd J Old; Jonathan Cebon Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: L Dyrskjøt; K Zieger; T Kissow Lildal; T Reinert; O Gruselle; T Coche; M Borre; T F Ørntoft Journal: Br J Cancer Date: 2012-05-17 Impact factor: 7.640
Authors: Frances R Wadelin; Joel Fulton; Hilary M Collins; Nikolaos Tertipis; Andrew Bottley; Keith A Spriggs; Franco H Falcone; David M Heery Journal: PLoS One Date: 2013-02-27 Impact factor: 3.240